Artivion Past Earnings Performance

Past criteria checks 0/6

Artivion's earnings have been declining at an average annual rate of -20.4%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 8% per year.

Key information

-20.4%

Earnings growth rate

-19.1%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate8.0%
Return on equity-0.3%
Net Margin-0.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Artivion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CYL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24385-119129
30 Jun 24377-818929
31 Mar 24368-1018828
31 Dec 23354-3118529
30 Sep 23340-2418029
30 Jun 23329-2817535
31 Mar 23320-2917136
31 Dec 22314-1916639
30 Sep 22314-4117040
30 Jun 22309-1716838
31 Mar 22305-1516338
31 Dec 21299-1516136
30 Sep 21287214533
30 Jun 21280-1214128
31 Mar 21258-1313526
31 Dec 20253-1713724
30 Sep 20255-1414323
30 Jun 20258-1114323
31 Mar 20275-514524
31 Dec 19276214323
30 Sep 19274214824
30 Jun 19271314023
31 Mar 19268114023
31 Dec 18263-314123
30 Sep 18248-512823
30 Jun 18227-512722
31 Mar 18207-211621
31 Dec 17190410119
30 Sep 17182910017
30 Jun 17183119616
31 Mar 17182109415
31 Dec 16180119213
30 Sep 16175107812
30 Jun 1616797611
31 Mar 1615577411
31 Dec 1514647210
30 Sep 1514337410
30 Jun 151443769
31 Mar 151436748
31 Dec 141457749
30 Sep 1414214729
30 Jun 1414115699
31 Mar 1414015689

Quality Earnings: CYL is currently unprofitable.

Growing Profit Margin: CYL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CYL is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.

Accelerating Growth: Unable to compare CYL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: CYL has a negative Return on Equity (-0.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 00:27
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jason MillsCanaccord Genuity
Raymond MyersEmerging Growth Equities, Ltd.